- News>
- Companies & Commodities
Cipla to ship anti-Aids drugs to Malaysia in two months
New Delhi, Mar 02: After receiving the first-ever compulsory licence (CL) from the Malaysian government for the supply of anti-retrovirals, domestic pharma major Cipla Ltd is likely to ship its maiden consignment of anti-Aids drugs to Malaysia in the next two months.
New Delhi, Mar 02: After receiving the first-ever compulsory licence (CL) from the Malaysian government for the supply of anti-retrovirals, domestic pharma major Cipla Ltd is likely to ship its maiden consignment of anti-Aids drugs to Malaysia in the next
two months.
''We expect to ship our first consignment as soon as orders are
received and it may happen in the next two months.”
''We will sell three active pharma ingredients to Malaysia for exclusive supply to government hospitals for the next two years,'' Cipla joint managing director Amar Lulla told.
Cipla will export chemically-equivalent versions of didanosine 100 mg and 25 mg tablets, produced originally by Bristol-Myers Squibb (BMS), and zidovudine 100 mg capsule and the combination drug lamivudine 150 mg and zidovudine 300 mg tablet both from Glaxosmithkline (GSK).
The Malaysian government has authorised its domestic firm Syarikat Megah Pharma and vaccines to hold a CL to import four specified anti-retroviral formulations from Cipla, Mr Lulla said, adding that the authorisation is valid for two years, commencing November last year.
Bureau Report
''We will sell three active pharma ingredients to Malaysia for exclusive supply to government hospitals for the next two years,'' Cipla joint managing director Amar Lulla told.
Cipla will export chemically-equivalent versions of didanosine 100 mg and 25 mg tablets, produced originally by Bristol-Myers Squibb (BMS), and zidovudine 100 mg capsule and the combination drug lamivudine 150 mg and zidovudine 300 mg tablet both from Glaxosmithkline (GSK).
The Malaysian government has authorised its domestic firm Syarikat Megah Pharma and vaccines to hold a CL to import four specified anti-retroviral formulations from Cipla, Mr Lulla said, adding that the authorisation is valid for two years, commencing November last year.
Bureau Report